Adcock Ingram's Urizone Wins Trademark Battle

Adcock Ingram's Urizone receives legal protection as the court halts Cipla's Furizome, citing trademark infringement.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Tagged Adcock Ingram, Cipla, Fosfomycin, FURIZOME, Intellectual Property, Litigation, Passing Off, Pharmaceutical Industry, SAHPRA, Schedule 4 Medicine, South Africa, Trademark Law, Unlawful Competition, URIZONE, UTI Treatment